Acutaas Chemicals Limited (NSE:ACUTAAS) announced its unaudited standalone and consolidated financial results for the quarter ended 30 June 2026 on 24 July 2026, following Board approval. The consolidated revenue from operations declined to Rs 32,967.48 lakhs in Q1 FY27 from Rs 43,275.05 lakhs in the prior quarter, while profit for the period stood at Rs 7,499.27 lakhs.
Key Highlights
- Consolidated revenue from operations fell to Rs 32,967.48 lakhs in Q1 FY27 from Rs 43,275.05 lakhs in Q4 FY26, representing a sequential decline of 23.9 percent.
- Profit for the period on a consolidated basis was Rs 7,499.27 lakhs in Q1 FY27 compared to Rs 13,428.37 lakhs in Q4 FY26, a sequential fall of 44.1 percent.
- Basic earnings per share (not annualised) were Rs 9.07 per share of face value Rs 5 in Q1 FY27, down from Rs 16.09 in the prior quarter.
- Total comprehensive income for the period declined to Rs 7,283.27 lakhs from Rs 13,112.38 lakhs sequentially, driven by lower profitability and exchange losses on translation of foreign subsidiaries.
- The board noted a GST and Central Excise anti-evasion inspection conducted at the company's Surat facility on 22-23 June 2026; management expects no material impact on financial position or operations.
- Acutaas Chemicals Electrolytes Private Limited, a subsidiary, issued partly paid-up shares to A.R.Z Pharma Ltd, resulting in the company's shareholding dilution from 100 percent to 90 percent effective 19 May 2026.
About the Company
Acutaas Chemicals Limited (NSE:ACUTAAS), formerly known as Ami Organics Limited, is engaged in the custom synthesis and manufacturing of speciality chemicals with applications in pharmaceuticals, active pharmaceutical ingredients (APIs), and allied sectors. The company is incorporated in India under the Companies Act and holds CIN L24100GJ2007PLC051093. Registered at Plot No. 440/4, 5 and 6, Road No. 82/A, GIDC Sachin, Surat, Gujarat 394230, the company operates manufacturing facilities in Surat. The company's consolidated financial statements include results from subsidiary entities: Acutaas Chemicals Electrolytes Private Limited, Acutaas Advance Material Limited, and Baba Fine Chemicals (partnership firm), as well as step-down subsidiaries Enchem Ami Organics Private Limited and Indichem Inc., and joint venture Ami Onco-Theronostics LLC.
Announcement in Detail
The Board of Directors of Acutaas Chemicals Limited met on 24 July 2026 and approved the unaudited consolidated and standalone financial results for the quarter ended 30 June 2026. The results were reviewed and recommended by the Audit Committee prior to board approval. The company's statutory auditors, M/s. Maheshwari & Co. Chartered Accountants, issued a limited review report on the consolidated financial statements with no modifications. The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS), specifically Ind AS 34 for interim financial reporting, as prescribed under Section 133 of the Companies Act 2013, and comply with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.
On a consolidated basis, the company reported total income of Rs 33,147.61 lakhs in Q1 FY27, comprising revenue from operations of Rs 32,967.48 lakhs and other income of Rs 180.13 lakhs. Total expenses amounted to Rs 22,756.60 lakhs, yielding profit before exceptional items and tax of Rs 10,391.01 lakhs. After provision for current tax of Rs 2,725.60 lakhs and deferred tax of Rs 166.14 lakhs, the company recorded profit for the period of Rs 7,499.27 lakhs. Other comprehensive loss of Rs 216.00 lakhs, primarily comprising exchange differences on translation of foreign subsidiary financial statements, resulted in total comprehensive income of Rs 7,283.27 lakhs. Profit attributable to owners of the company was Rs 7,426.01 lakhs, with non-controlling interests accounting for Rs 73.26 lakhs.
The company operates as a single operating segment focused on custom synthesis and manufacturing of speciality chemicals for pharmaceutical and API applications. During the quarter, Acutaas Chemicals Electrolytes Private Limited (ACEPL), a subsidiary, issued partly paid-up equity shares to A.R.Z Pharma Ltd, diluting the company's shareholding in ACEPL from 100 percent to 90 percent effective 19 May 2026. The company confirmed this dilution has not resulted in any loss of control over ACEPL. Additionally, the Central Goods and Service Tax (CGST) and Central Excise Anti-Evasion Department conducted inspection and search proceedings at the company's registered office and Surat manufacturing facility on 22 and 23 June 2026. Management stated that based on information available at the time of financial result approval, no material impact is expected on the company's financial position, results of operations, or cash flows from this inspection.
Impact on Investors
Investors will note that consolidated revenue and profitability both declined significantly on a sequential quarter basis. Revenue from operations fell 23.9 percent to Rs 32,967.48 lakhs from the prior quarter's Rs 43,275.05 lakhs, while profit for the period contracted 44.1 percent to Rs 7,499.27 lakhs from Rs 13,428.37 lakhs. The sharper percentage decline in profit relative to revenue suggests either increased cost pressures, higher financing costs, or changes in operating leverage during the quarter. Year-on-year, however, revenue grew 59.0 percent (from Rs 20,723.72 lakhs in Q1 FY26) and profit surged 69.9 percent (from Rs 4,401.05 lakhs), indicating underlying business momentum despite seasonal or quarterly volatility. Basic earnings per share (not annualised) of Rs 9.07 reflect the sequential profit decline but remain elevated compared to Rs 5.41 in the corresponding prior-year quarter.
The dilution of the company's shareholding in Acutaas Chemicals Electrolytes Private Limited from 100 percent to 90 percent, effective 19 May 2026, results in reduced economic ownership of that subsidiary going forward, though management control remains intact. Shareholders should note that this partly paid-up share issuance to A.R.Z Pharma Ltd may dilute future earnings attribution from ACEPL. Additionally, the CGST and Central Excise anti-evasion inspection at the company's manufacturing facility in Surat, conducted 22-23 June 2026, represents a regulatory development that shareholders should monitor. While management expects no material financial impact based on information available at result approval, investors will observe that the timing of this inspection (mid-quarter) and the absence of specific details in the filing suggest the matter was still under assessment and full implications may not yet be known.
Sector / Market Context
Acutaas Chemicals operates in the speciality chemicals sector, with focus on custom synthesis and manufacturing for pharmaceuticals and active pharmaceutical ingredients. India's pharmaceutical and speciality chemicals sectors remain driven by global outsourcing of drug manufacturing and API production to contract manufacturers. The company's Q1 FY27 performance reflects both seasonal factors typical in chemical manufacturing and broader market conditions. For context, India's chemical and petrochemical industry saw production of approximately 214 million tonnes in FY26 according to government data, with speciality chemicals representing a growing segment driven by pharmaceutical demand and export-oriented manufacturing. The company's consolidated structure, which includes multiple domestic subsidiaries and a joint venture, positions it to capture opportunities across the pharmaceutical supply chain, though foreign exchange volatility (evidenced by the Rs 209.36 lakhs exchange loss recognised in Q1) remains a material factor for entities with international operations.